US 12,338,214 B2
Bexarotene derivatives and their use in treating cancer
Donald Tsai, Los Angeles, CA (US); and David Kaelin, Los Angeles, CA (US)
Assigned to DJ Therapeutics LLC, Long Beach, CA (US)
Appl. No. 16/971,736
Filed by DJ THERAPEUTICS LLC, Long Beach, CA (US)
PCT Filed Mar. 1, 2019, PCT No. PCT/US2019/020298
§ 371(c)(1), (2) Date Aug. 21, 2020,
PCT Pub. No. WO2019/169270, PCT Pub. Date Sep. 6, 2019.
Claims priority of provisional application 62/637,387, filed on Mar. 1, 2018.
Prior Publication US 2021/0363093 A1, Nov. 25, 2021
Int. Cl. C07C 63/66 (2006.01); A61P 35/00 (2006.01); C07C 63/49 (2006.01)
CPC C07C 63/66 (2013.01) [A61P 35/00 (2018.01); C07C 63/49 (2013.01); C07C 2602/10 (2017.05)] 24 Claims
 
1. A compound of formula:

OG Complex Work Unit Chemistry
or pharmaceutically acceptable salts thereof, wherein
two R groups and the carbon atom to which they are attached form ═CH2 or cyclopropyl ring;
R1 is —CO2H;
R2 is halogen or methyl;
R3 is halogen;
R4 and R5 are independently C1-C6 alkyl or C1-C6 haloalkyl, or R4 and R5 are together with the carbon atoms to which they are attached form C3 cycloalkyl optionally substituted with one or more R8;
R6 and R7 are independently C1-C6 alkyl or C1-C6 haloalkyl, or R6 and R7 are together with the carbon atoms to which they are attached form C3 cycloalkyl optionally substituted with one or more R8;
wherein each R8 is independently halogen, —NO2, —CN, C1-C6 alkyl, C1-C6 haloalkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —OH, C1-C6 alkoxy, or C1-C6 haloalkoxy.